DRT-101
Categoría
Drugs National Companies
Tipo de registro
Biotech Sanitaria
Nombre socio
Producto / Servicio
DRT-101
Tipo
Biodrugs/ Drugs
Area terapéutica
Abuso de sustancias
Analgesia / Dolor
Sistema nervioso central
Propiedades/Indicación
Cannabis Use Disorder (CUD) treatment: The lead asset, DRT-101, is an oral peptide-based drug candidate currently in the preclinical stage, specifically designed to modulate the interaction between cannabinoid CB1 and serotonin 5-HT2A receptors in the brain—a molecular target recently identified as critical in cannabis-induced addiction and cognitive decline. DRT-101 is intended to reduce compulsive cannabis consumption, cravings, cognitive impairment, and loss of control. Beyond recreational use, this strategy also offers a safe option for patients requiring medical cannabis, allowing them to benefit from its analgesic properties at controlled doses without developing dependence or experiencing memory loss.
Aplicación
Pharmaceutical industry, biotechnology companies, and the neuropharmacology and mental health sectors. The primary application is in the treatment of cannabis use disorder, while the mechanism of action also enables safer medical cannabis use by preventing the development of addiction and memory impairment. Potential applications further extend to innovative therapies for psychiatric disorders, in collaboration with academic, clinical, and industrial partners.
Fase de desarrollo
Preclinical
Fases desarrolladas en España
Preclinical
Localización de la Investigación
España
Patente
✔